{"cited_by_count":195255,"description":"This cluster of papers focuses on the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as palbociclib, letrozole, ribociclib, and abemaciclib, in the treatment of hormone receptor-positive metastatic breast cancer. The papers cover various aspects including clinical trials, mechanisms of action, therapeutic resistance, combination strategies, and potential biomarkers.","display_name":"Advanced Breast Cancer Therapies","domain_id":"4","external_ids":{"openalex":"https://openalex.org/T12829","wikipedia":"https://en.wikipedia.org/wiki/Palbociclib#Breast_cancer_therapy"},"field_id":"27","id":"T12829","keywords":[{"display_name":"CDK4/6 inhibitors","id":"cdk4-6-inhibitors","score":0.6034,"url":"https://openalex.org/keywords/cdk4-6-inhibitors"},{"display_name":"palbociclib","id":"palbociclib","score":0.5724,"url":"https://openalex.org/keywords/palbociclib"},{"display_name":"hormone receptor-positive breast cancer","id":"hormone-receptor-positive-breast-cancer","score":0.215,"url":"https://openalex.org/keywords/hormone-receptor-positive-breast-cancer"},{"display_name":"fulvestrant","id":"fulvestrant","score":0.3364,"url":"https://openalex.org/keywords/fulvestrant"},{"display_name":"HER2-negative breast cancer","id":"her2-negative-breast-cancer","score":0.2269,"url":"https://openalex.org/keywords/her2-negative-breast-cancer"},{"display_name":"ribociclib","id":"ribociclib","score":0.661,"url":"https://openalex.org/keywords/ribociclib"},{"display_name":"abemaciclib","id":"abemaciclib","score":0.5825,"url":"https://openalex.org/keywords/abemaciclib"},{"display_name":"endocrine therapy resistance","id":"endocrine-resistance","score":0.237,"url":"https://openalex.org/keywords/endocrine-resistance"},{"display_name":"hormone receptor-positive HER2-negative breast cancer","id":"hr-her2-breast-cancer","score":0.464,"url":"https://openalex.org/keywords/hr-her2-breast-cancer"},{"display_name":"ESR1 mutations","id":"esr1-mutations","score":0.4687,"url":"https://openalex.org/keywords/esr1-mutations"},{"display_name":"CDK4/6 inhibitor resistance","id":"cdk4-6-inhibitor-resistance","score":0.7944,"url":"https://openalex.org/keywords/cdk4-6-inhibitor-resistance"},{"display_name":"exemestane","id":"exemestane","score":0.2289,"url":"https://openalex.org/keywords/exemestane"},{"display_name":"alpelisib","id":"alpelisib","score":0.2855,"url":"https://openalex.org/keywords/alpelisib"},{"display_name":"selective estrogen receptor degrader","id":"selective-estrogen-receptor-degrader","score":0.5275,"url":"https://openalex.org/keywords/selective-estrogen-receptor-degrader"},{"display_name":"HR+/HER2- metastatic breast cancer","id":"hr-her2-metastatic-breast-cancer","score":0.7862,"url":"https://openalex.org/keywords/hr-her2-metastatic-breast-cancer"},{"display_name":"aromatase inhibitor resistance","id":"aromatase-inhibitor-resistance","score":0.3511,"url":"https://openalex.org/keywords/aromatase-inhibitor-resistance"},{"display_name":"cyclin-dependent kinase 4/6 inhibitors","id":"cyclin-dependent-kinase-4-6-inhibitors","score":0.6758,"url":"https://openalex.org/keywords/cyclin-dependent-kinase-4-6-inhibitors"},{"display_name":"HR+/HER2- advanced breast cancer","id":"hr-her2-advanced-breast-cancer","score":0.8247,"url":"https://openalex.org/keywords/hr-her2-advanced-breast-cancer"},{"display_name":"clinical benefit rate","id":"clinical-benefit-rate","score":0.2315,"url":"https://openalex.org/keywords/clinical-benefit-rate"},{"display_name":"ER-positive HER2-negative breast cancer","id":"er-positive-her2-negative-breast-cancer","score":0.281,"url":"https://openalex.org/keywords/er-positive-her2-negative-breast-cancer"},{"display_name":"elacestrant","id":"elacestrant","score":0.6987,"url":"https://openalex.org/keywords/elacestrant"},{"display_name":"HER2-negative metastatic breast cancer","id":"her2-negative-metastatic-breast-cancer","score":0.3421,"url":"https://openalex.org/keywords/her2-negative-metastatic-breast-cancer"},{"display_name":"first-line endocrine therapy","id":"first-line-endocrine-therapy","score":0.6871,"url":"https://openalex.org/keywords/first-line-endocrine-therapy"},{"display_name":"capivasertib","id":"capivasertib","score":0.2827,"url":"https://openalex.org/keywords/capivasertib"},{"display_name":"nonsteroidal aromatase inhibitors","id":"nonsteroidal-aromatase-inhibitors","score":0.3594,"url":"https://openalex.org/keywords/nonsteroidal-aromatase-inhibitors"}],"legacy_keywords":["CDK4/6 Inhibitors","Breast Cancer","Palbociclib","Letrozole","Ribociclib","Abemaciclib","Hormone Receptor-Positive","Metastatic Breast Cancer","Cell Cycle Control","Therapeutic Resistance"],"openalex_id":"https://openalex.org/T12829","source_created_date":"2024-01-23T15:27:15","source_updated_date":"2026-10-17T03:02:00","subfield_id":"2740","url":"/topics/T12829","works_api_url":"https://api.openalex.org/works?filter=topics.id:T12829","works_count":16053,"label":"Advanced Breast Cancer Therapies","provider":"openalex","revision":"e5c9e52f2a554e9f","taxonomy_revision":"f050b5d4780b1289","title":"Advanced Breast Cancer Therapies","kind":"topic-directory","aeo_cohort":"topic-directory","catalogue_revision":"f050b5d4780b1289","numeric_address":"38351791289445674","address_version":"morton4x16-v1","coordinates":[4,27,2740,12829],"answer_status":"Directory metadata; local answer requires separate source review","truth_status":"Subject descriptor, not a factual answer or a demonstrated knowledge gap","reviewed_answer":null}